Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Investigational Drugs Right
  3. Mirikizumab Right
  4. How soon does mirikizumab start working for the symptoms of ulcerative colitis?
Enter Mirikizumab (Search)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mirikizumab

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling.

How soon does mirikizumab start working for the symptoms of ulcerative colitis?

As early as week 2, mirikizumab was associated with significantly greater improvements in stool frequency, rectal bleeding, bowel urgency, and fatigue as well as higher stool frequency remission rates than placebo.

US_cFAQ_MIR715B_ONSET_EFFICACY_UC
US_cFAQ_MIR715B_ONSET_EFFICACY_UC
en-US

LUCENT-1 Study Design

LUCENT-1 is a 12-week, phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled study of mirikizumab, a p19-directed anti-interleukin(IL)-23 antibody. The study was conducted to evaluate efficacy and safety in adult patients with moderately-to-severely active ulcerative colitis, with a Modified Mayo score of 4 to 9 points and centrally read Mayo endoscopic subscore ≥2, who had an inadequate response, loss of response, or an intolerance to corticosteroids, immunosuppressants, biologic therapies, or tofacitinib.1

A total of 1281 patients were randomized in a 3:1 ratio to receive intravenous mirikizumab 300 mg or placebo every 4 weeks. Randomization was stratified by

  • biologic failure status
  • baseline corticosteroid use
  • baseline disease activity as measured by the Modified Mayo score, and
  • world region.1

Ulcerative Colitis Symptom Control During the 12-Week LUCENT-1 Induction Study

Appendix shows definitions for the symptom endpoints and outcomes, as mentioned in the following sections.

Improvement in Stool Frequency

As early as week 2, patients who received mirikizumab had significantly greater reductions from baseline in stool frequency compared with placebo (p<.05) (Change in Stool Frequency in LUCENT-1).2,3

Change in Stool Frequency in LUCENT-13

Figure 1 description: The least-squares mean change from baseline in stool frequency was significantly greater in the mirikizumab group than in the placebo group at weeks 2 (p<.05), 4 (p<.001), 8 (p<.001), and 12 (p<.001). At week 12, the least-squares mean reduction from baseline in stool frequency was 1.06 for mirikizumab and 0.71 for placebo.

Abbreviations: IV = intravenous; LSM = least-squares mean; MIRI = mirikizumab; MMRM = mixed measures repeated model; PBO = placebo.

* p<.05.
*** p<.001.

Improvement in Rectal Bleeding

As early as week 2, patients who received mirikizumab had significantly greater reductions from baseline in rectal bleeding compared with placebo (p<.01) (Change in Rectal Bleeding in LUCENT-1).2,3

Change in Rectal Bleeding in LUCENT-13

Figure 2 description: The least-squares mean change from baseline in rectal bleeding was significantly greater in the mirikizumab group than in the placebo group at weeks 2 (p<.01), 4 (p<.001), 8 (p<.001), and 12 (p<.001). At week 12, the least-squares mean reduction from baseline in rectal bleeding was 1.01 for mirikizumab and 0.75 for placebo.

Abbreviations: IV = intravenous; LSM = least-squares mean; MIRI = mirikizumab; MMRM = mixed measures repeated model; PBO = placebo.

** p<.01.
*** p<.001.

Improvement in Bowel Urgency

As early as week 2, patients who received mirikizumab had significantly greater reductions from baseline in bowel urgency compared with placebo (p<.01) (Change in Bowel Urgency in LUCENT-1).2,3

Change in Bowel Urgency in LUCENT-13

Figure 3 description: The least-squares mean change from baseline in bowel urgency was significantly greater in the mirikizumab group than in the placebo group at weeks 2 (p<.01), 4 (p<.001), 8 (p<.001), and 12 (p<.001). At week 12, the least-squares mean reduction from baseline in bowel urgency was 2.59 for mirikizumab and 1.63 for placebo.

Abbreviations: IV = intravenous; LSM = least-squares mean; MIRI = mirikizumab; MMRM = mixed measures repeated model; PBO = placebo.

** p<.01.
*** p<.001.

Stool Frequency Remission

As early as week 2, a significantly greater proportion of patients who received mirikizumab achieved stool frequency remission than did patients who received placebo (p<.05) (Stool Frequency Remission Rates in LUCENT-1).2,3

Stool Frequency Remission Rates in LUCENT-13

Figure 4 description: The proportion of patients who achieved stool frequency remission was significantly higher in the mirikizumab group than in the placebo group at weeks 2 (p<.05), 4 (p<.001), 8 (p<.001), and 12 (p<.001). At week 12, 57.0% of patients in the mirikizumab group and 39.8% of patients in the placebo group had achieved stool frequency remission.

Abbreviations: IV = intravenous; MIRI = mirikizumab; NRI = nonresponder imputation; PBO = placebo.

* p<.05.
*** p<.001.

Note: Stool frequency remission is defined as a stool frequency subscore of 0, or stool frequency subscore of 1 with ≥1-point decrease from baseline.

Rectal Bleeding Remission

As early as week 4, a significantly greater proportion of patients who received mirikizumab achieved rectal bleeding remission than did patients who received placebo (p<.05) (Rectal Bleeding Remission Rates in LUCENT-1).2,3

Rectal Bleeding Remission Rates in LUCENT-13

Figure 5 description: The proportion of patients who achieved rectal bleeding remission was significantly higher in the mirikizumab group than in the placebo group at weeks 4 (p<.05), 8 (p<.001), and 12 (p<.001). At week 12, 63.9% of patients in the mirikizumab group and 43.9% of patients in the placebo group had achieved rectal bleeding remission.

Abbreviations: IV = intravenous; MIRI = mirikizumab; NRI = nonresponder imputation; PBO = placebo.

* p<.05.
*** p<.001.

Note: Rectal bleeding remission is defined as a rectal bleeding subscore of 0.

Symptomatic Response

As early as week 2, a significantly greater proportion of patients who received mirikizumab achieved symptomatic response than did patients who received placebo (p<.01) (Symptomatic Response Rates in LUCENT-1).2,3

Symptomatic Response Rates in LUCENT-13

Figure 6 description: The proportion of patients who achieved symptomatic response was significantly higher in the mirikizumab group than in the placebo group at weeks 2 (p<.01), 4 (p<.001), 8 (p<.001), and 12 (p<.001). At week 12, 72.0% of patients in the mirikizumab group and 52.4% of patients in the placebo group had achieved symptomatic response.

Abbreviations: IV = intravenous; MIRI = mirikizumab; NRI = nonresponder imputation; PBO = placebo.

** p<.01.
*** p<.001.

Note: Symptomatic response is defined as a reduction ≥30% from baseline in the sum of stool frequency and rectal bleeding subscores.

Symptomatic Remission

As early as week 4, a significantly greater proportion of patients who received mirikizumab achieved symptomatic remission than did patients who received placebo (p<.001) (Symptomatic Remission Rates in LUCENT-1).2,3

Symptomatic Remission Rates in LUCENT-13

Figure 7 description: The proportion of patients who achieved symptomatic remission was significantly higher in the mirikizumab group than in the placebo group at weeks 4 (p<.001), 8 (p<.001), and 12 (p<.001). At week 12, 45.5% of patients in the mirikizumab group and 27.9% of patients in the placebo group had achieved symtpomatic remission.

Abbreviations: IV = intravenous; MIRI = mirikizumab; NRI = nonresponder imputation; PBO = placebo.

*** p<.001.

Note: Symptomatic remission is defined as (1) a stool frequency subscore of 0, or stool frequency subscore of 1 with ≥1-point decrease from baseline, and (2) rectal bleeding subscore of 0.

Bowel Urgency Clinically Meaningful Improvement

As early as week 4, a significantly greater proportion of patients who received mirikizumab achieved a clinically meaningful improvement in bowel urgency than did patients who received placebo (p<.05) (Bowel Urgency Clinically Meaningful Improvement in LUCENT-1).2,3

Bowel Urgency Clinically Meaningful Improvement in LUCENT-13

Figure 8 description: The proportion of patients who achieved a clinically meaningful improvement in bowel urgency was significantly higher in the mirikizumab group than in the placebo group at weeks 4 (p<.05), 8 (p<.001), and 12 (p<.001). At week 12, 48.7% of patients in the mirikizumab group and 32.2% of patients in the placebo group had achieved a clinically meaningful improvement in bowel urgency.

Abbreviations: IV = intravenous; MIRI = mirikizumab; NRI = nonresponder imputation; NRS = Numeric Rating Scale; PBO = placebo.

* p<.05.
*** p<.001.

Note: Clinically meaningful is defined as an improvement ≥3 points in the Urgency NRS in patients with a baseline Urgency NRS ≥3.

Bowel Urgency Remission

At week 8, a significantly greater proportion of patients who received mirikizumab achieved bowel urgency remission than did patients who received placebo (p<.01) (Bowel Urgency Remission Rates in LUCENT-1).2,3

Bowel Urgency Remission Rates in LUCENT-13

Figure 9 description: The proportion of patients who achieved bowel urgency remission was significantly higher in the mirikizumab group than in the placebo group at weeks 8 (p<.01) and 12 (p<.001). At week 12, 22.1% of patients in the mirikizumab group and 12.3% of patients in the placebo group had achieved bowel urgency remission.

Abbreviations: IV = intravenous; MIRI = mirikizumab; NRI = nonresponder imputation; NRS = Numeric Rating Scale; PBO = placebo.

** p<.01.
*** p<.001.

Note: Bowel urgency remission is defined as Urgency NRS=0 or 1 among patients induced into clinical response with mirikizumab in LUCENT-1 and had Urgency NRS ≥3 at induction baseline.

Fatigue Numeric Rating Scale

As early as week 2, patients who received mirikizumab had significantly greater reductions from baseline in the fatigue Numeric Rating Scale compared with placebo (p<.05) (Change in Fatigue Numeric Rating Scale in LUCENT-1).2,3 

Change in Fatigue Numeric Rating Scale in LUCENT-13

Figure 10 description: The least-squares mean change from baseline in fatigue Numeric Rating Scale was significantly greater in the mirikizumab group than in the placebo group at weeks 2 (p<.05), 4 (p<.001), 8 (p<.001), and 12 (p<.001). At week 12, the least-squares mean reduction from baseline in fatigue Numeric Rating Scale was 1.96 for mirikizumab and 1.29 for placebo. 

Abbreviations: IV = intravenous; LSM = least-squares mean; MIRI = mirikizumab; MMRM = mixed model for repeated measures; PBO = placebo.

* p<.05.
*** p<.001.

Abdominal Pain Improvement

As early as week 4, a significantly greater proportion of patients who received mirikizumab achieved abdominal pain improvement than did patients who received placebo (p<.01) (Abdominal Pain Improvement in LUCENT-1).2,3

Abdominal Pain Improvement in LUCENT-13

Figure 11 description: The proportion of patients who achieved abdominal pain improvement was significantly higher in the mirikizumab group than in the placebo group at weeks 4 (p<.01), 8 (p<.001) and 12 (p<.001). At week 12, 66.4% of patients in the mirikizumab group and 49.2% of patients in the placebo group had achieved abdominal pain improvement.

Abbreviations: IV = intravenous; MIRI = mirikizumab; NRI = nonresponder imputation; PBO = placebo.

** p<.01.
*** p<.001.

Note: Improvement in abdominal pain is defined as an improvement ≥30% from induction baseline in patients with a baseline abdominal pain Numeric Rating Scale ≥3.

Additional Information

Additional safety and efficacy data from the mirikizumab ulcerative colitis registration studies are available in the following document:

What were the results of the phase 3 clinical trials of mirikizumab for the treatment of ulcerative colitis in adults?

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1D'Haens G, Kobayashi T, Morris N, et al. Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study. J Crohns Colitis. 2022;16(suppl 1):i028-i029. European Crohn's and Colitis Organisation abstract OP26. https://doi.org/10.1093/ecco-jcc/jjab232.025

2Danese S, Dignass A, Matsuoka K, et al. Early symptom control with mirikizumab in patients with moderately to severely active ulcerative colitis in the LUCENT-1 induction trial. Abstract presented at: United European Gastroenterology Week (UEGW); October 8-11, 2022.

3Danese S, Dignass A, Matsuoka K, et al. Early symptom control with mirikizumab in patients with moderately to severely active ulcerative colitis in the LUCENT-1 induction trial. Poster presented at: United European Gastroenterology Week (UEGW); October 8-11, 2022.

4Dignass A, Danese S, Matsuoka K, et al. Sustained symptom control with mirikizumab in patients with moderately to severely active ulcerative colitis in the LUCENT-2 maintenance trial. Abstract presented at: United European Gastroenterology Week (UEGW); October 8-11, 2022.

5Dubinsky MC, Irving PM, Panaccione R, et al. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient Rep Outcomes. 2022;6(1):31. https://dx.doi.org/10.1186/s41687-022-00439-w

6Dubinsky MC, Delbecque L, Lewis JD, et al. Psychometric validation and interpretation of a patient-reported outcomes instrument to assess bowel urgency among adults with moderate to severe ulcerative colitis. Abstract presented at: 17th Congress of the European Crohn’s and Colitis Organisation (ECCO Virtual); February 16-19, 2022. Accessed June 15, 2022. https://www.ecco-ibd.eu/publications/congress-abstracts/item/p138-psychometric-validation-and-interpretation-of-a-patient-reported-outcomes-instrument-to-assess-bowel-urgency-among-adults-with-moderate-to-severe-ulcerative-colitis.html

Appendix

Symptom Control Endpoint Definitions

 Definitions of Ulcerative Colitis Symptom Control Endpoints in the LUCENT Clinical Trial Program2,4-6

Outcome

Definition

Stool frequency remission

Stool frequency subscore of 0, or stool frequency subscore of 1 with ≥1-point decrease from baseline.

Rectal bleeding remission

Rectal bleeding subscore of 0.

Symptomatic response

Reduction ≥30% from baseline in the sum of stool frequency and rectal bleeding subscores.

Symptomatic remission

Stool frequency subscore of 0, or stool frequency subscore of 1 with ≥1-point decrease from baseline, and rectal bleeding subscore of 0.

Stable maintenance of symptomatic remission

Symptomatic remission for at least 7 of 9 visits from weeks 4 to 36 and also at week 40, among patients in symptomatic remission and clinical response at the end of LUCENT-1.

Bowel urgency NRS

The bowel urgency NRS is an 11-point scale ranging from

  • 0, indicating no bowel urgency, to
  • 10, indicating the worst possible bowel urgency.

Bowel urgency remission

Defined as Urgency NRS=0 or 1 among patients induced into clinical response with mirikizumab in LUCENT-1 and had Urgency NRS ≥3 at induction baseline.

Bowel urgency CMI

Improvement ≥3 points in the Urgency NRS in patients with a baseline Urgency NRS ≥3.

Improvement in abdominal pain

Improvement ≥30% from induction baseline in patients with a baseline abdominal pain NRS ≥3.

Abbreviation: CMI = Clinically Meaningful Improvement; NRS = Numeric Rating Scale.

Patient-Reported Outcomes Scales

Patient-Reported Outcomes Scales Assessed in the Daily Patient eDiary3

Patient-reported outcomes assessed in the daily patient eDiary included the...

which ranges in scores from...

to...

stool frequency Mayo subscore

0 (normal number of stools/day for the patient)

4 (≥5 stools/day more than normal for the patient).

rectal bleeding Mayo subscore

0 (no blood)

3 (blood alone passed).

bowel urgency severity NRS

0 (no urgency)

10 (worst possible urgency).

abdominal pain NRS

0 (none)

10 (worst possible pain).

fatigue NRS

0 (none)

10 (worst possible fatigue).

Abbreviation: NRS = Numeric Rating Scale.

Note: Patient-reported outcomes were recorded daily in the patient eDiary then averaged by week. For stool frequency and rectal bleeding, weekly assessments were calculated by averaging the 3 most recent available diary days in a 7-day period. For bowel urgency, abdominal pain, and fatigue, all available diary days in a 7-day period were averaged.

Date of Last Review: October 11, 2022

Additional related information:

  • Early Symptom Control with Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial
Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly